The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review
Articolo
Data di Pubblicazione:
2023
Citazione:
The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review / A. Vitiello, M. Sabbatucci, A. Silenzi, A. Capuano, F. Rossi, A. Zovi, F. Blasi, G. Rezza. - In: RESPIRATORY RESEARCH. - ISSN 1465-993X. - 24:1(2023), pp. 278.1-278.10. [10.1186/s12931-023-02593-1]
Abstract:
Several risk factors for Coronavirus-2019 (COVID-19) disease have been highlighted in clinical evidence. Among
the various risk factors are advanced age, metabolic illness such as diabetes, heart disease, and diseases of the res-
piratory system. Cystic Fibrosis (CF) is a rare disease with autosomal recessive transmission, characterised by a lack
of synthesis of the CFTR channel protein, and multi-organ clinical symptoms mainly affecting the respiratory tract
with recurrent pulmonary exacerbations. In view of the pathophysiological mechanisms, CF disease should be
in theory considered a risk factor for SARS-CoV2 or severe COVID-19. However, recent clinical evidence seems to point
in the opposite direction, suggesting that CF could be a protective factor against severe COVID-19. Possibly, the lack
of presence or function of the CFTR channel protein could be linked to the expression of the membrane glycoprotein
ACE-2, a key enzyme for the endocellular penetration of SARS-CoV-2 and related to the pathophysiology of COVID-19
disease. Furthermore, CFTR channel modulating agents could indirectly influence the expression of ACE-2, play-
ing an important role in restoring the proper functioning of mucociliary clearance and the pulmonary microbiome
in the host response to SARS-CoV-2 infection. In this review, the authors attempt to shed light on these important
associations of issues that are not yet fully elucidated.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Cystic fibrosis; COVID-19; CFTR modulators; ACE-2; SARS-CoV-2; Angiotensins
Elenco autori:
A. Vitiello, M. Sabbatucci, A. Silenzi, A. Capuano, F. Rossi, A. Zovi, F. Blasi, G. Rezza
Link alla scheda completa: